Transport, Bioavailability, Safety, and Calmodulin-Dependent-Phosphodiesterase-Inhibitory Properties of Flaxseed-Derived Bioactive Peptides.
Animals
Biological Availability
Biological Transport
Caco-2 Cells
Cell Proliferation
/ drug effects
Cyclic Nucleotide Phosphodiesterases, Type 1
/ antagonists & inhibitors
Enzyme Inhibitors
/ administration & dosage
Female
Flax
/ chemistry
Humans
Male
Peptide Mapping
Peptides
/ administration & dosage
Rats
Rats, Wistar
Caco-2 cells
bioavailability
calmodulin
cytotoxicity
flaxseed
intestinal epithelium
peptide transport
phosphodiesterase
Journal
Journal of agricultural and food chemistry
ISSN: 1520-5118
Titre abrégé: J Agric Food Chem
Pays: United States
ID NLM: 0374755
Informations de publication
Date de publication:
06 Feb 2019
06 Feb 2019
Historique:
pubmed:
11
1
2019
medline:
21
3
2019
entrez:
11
1
2019
Statut:
ppublish
Résumé
The aim of this work was to determine bioavailability and in vivo calmodulin-dependent-phosphodiesterase (CaMPDE)-inhibitory activity of six flaxseed-protein-derived peptides (AGA, AKLMS, QIAK, RWIQ, QQAKQ, and KQLSTGC) after oral administration to Wistar rats. Initial experiments tested the cytotoxicity and cellular-transport potentials of the peptides using Caco-2 cells. The cytotoxicity assay indicated that none of the six peptides had an adverse effect on the proliferation and viability of the Caco-2 cells, whereas the transport assay confirmed peptide translocation across the cell membrane. However, only two of the peptides (AGA and RWIQ) were detected in the rat serum up to 90 min postgavage, with traces of RWIQ persisting in serum 1 week after oral gavage. The six peptides inhibited plasma activity of CaMPDE with AGA (34.63%), QIAK (36.66%), and KQLSTGC (34.21%) being the most effective 30 min after gavage. In contrast, only AGA maintained significant plasma-CaMPDE-activity inhibition (44.35%) after 60 min.
Identifiants
pubmed: 30628451
doi: 10.1021/acs.jafc.8b06299
doi:
Substances chimiques
Enzyme Inhibitors
0
Peptides
0
Cyclic Nucleotide Phosphodiesterases, Type 1
EC 3.1.4.17
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM